Mercer Global Advisors Inc. ADV Sells 720 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Mercer Global Advisors Inc. ADV trimmed its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 5.9% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 11,393 shares of the specialty pharmaceutical company’s stock after selling 720 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Supernus Pharmaceuticals were worth $305,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Edgestream Partners L.P. bought a new stake in Supernus Pharmaceuticals during the second quarter valued at about $2,029,000. Renaissance Technologies LLC increased its holdings in shares of Supernus Pharmaceuticals by 26.4% in the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock valued at $45,077,000 after purchasing an additional 351,900 shares during the period. Dimensional Fund Advisors LP raised its position in Supernus Pharmaceuticals by 12.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock worth $76,690,000 after buying an additional 309,966 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in Supernus Pharmaceuticals during the second quarter valued at $47,000. Finally, BOKF NA lifted its holdings in shares of Supernus Pharmaceuticals by 248.3% in the 2nd quarter. BOKF NA now owns 28,186 shares of the specialty pharmaceutical company’s stock valued at $754,000 after buying an additional 20,093 shares during the period.

Wall Street Analyst Weigh In

SUPN has been the topic of several recent research reports. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Piper Sandler cut Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $41.00 to $36.00 in a research report on Wednesday, September 11th.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $30.75 on Monday. Supernus Pharmaceuticals, Inc. has a 1-year low of $21.99 and a 1-year high of $35.44. The company has a market cap of $1.69 billion, a PE ratio of -106.03 and a beta of 0.88. The stock’s 50 day simple moving average is $32.27 and its 200-day simple moving average is $30.39.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The business had revenue of $168.30 million for the quarter, compared to analyst estimates of $148.83 million. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. The business’s revenue was up 24.1% compared to the same quarter last year. On average, equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.